Institute of Cellular and Integrative Neurosciences, CNRS, University of Strasbourg, Strasbourg, France.
Institute of Cellular and Integrative Neurosciences, CNRS, University of Strasbourg, Strasbourg, France.
Handb Clin Neurol. 2021;179:331-343. doi: 10.1016/B978-0-12-819975-6.00021-2.
Melatonin (MLT), secreted during the night by the pineal gland, is an efferent hormonal signal of the master circadian clock located in the suprachiasmatic nucleus (SCN). Consequently, it is a reliable phase marker of the SCN clock. If one defines as "chronobiotic," a drug able to influence the phase and/or the period of the circadian clock, MLT is a very potent one. The most convincing data obtained so far come from studies on totally blind individuals. Exogenous MLT administered daily entrains the sleep-wake cycle of these individuals to a 24-h cycle. MLT, however, is not essential to sleep. In nocturnally, active mammals, MLT is released during the night concomitantly with the daily period of wakefulness. Therefore, MLT cannot be simply considered as a sleep hormone, but rather as a signal of darkness. Its role in the circadian system is to reinforce nighttime physiology, including timing of the sleep-wake cycle and other circadian rhythms. MLT exerts its effects on the sleep cycle especially by a direct action on the master circadian clock. The sleep-wake cycle is depending not only on the circadian clock but also on an orchestrated network of different centers in the brain. Thus, the control of sleep-wake rhythm might be explained by a parallel and concomitant action of MLT on the master clock (chronobiotic effect) and on sleep-related structures within the brain. MLT acts through two high-affinity membrane receptors (MT1 and MT2) with striking differences in their distribution pattern. MLT is a powerful synchronizer of human circadian rhythms, thus justifying the use of MLT and MLT agonists in clinical medicine as pharmacological tools to manipulate the sleep-wake cycle, and to treat sleep disorders and other circadian disorders. Available MLT analogs/drugs are all nonspecific MT1/MT2 agonists. The development of new ligands which are highly selectivity for each subtype is clearly a new challenge for the field and will be at the root of new therapeutic agents for curing specific pathologies, including sleep disorders.
褪黑素(MLT)由松果腺在夜间分泌,是位于视交叉上核(SCN)的主生物钟的传出激素信号。因此,它是 SCN 时钟相位的可靠标志物。如果将能够影响生物钟相位和/或周期的药物定义为“chronobiotic”,那么 MLT 就是一种非常有效的药物。迄今为止,最令人信服的数据来自对完全失明个体的研究。每天给予外源性 MLT 可使这些个体的睡眠-觉醒周期与 24 小时周期同步。然而,MLT 对于睡眠并非必不可少。在夜间活动的哺乳动物中,MLT 在夜间与每日清醒期同时释放。因此,MLT 不能简单地被认为是一种睡眠激素,而更像是黑暗的信号。它在昼夜节律系统中的作用是增强夜间生理机能,包括睡眠-觉醒周期和其他昼夜节律的时间安排。MLT 通过对主生物钟的直接作用来发挥其对睡眠周期的作用。睡眠-觉醒周期不仅取决于生物钟,还取决于大脑中不同中枢的协调网络。因此,睡眠-觉醒节律的控制可能通过 MLT 对主时钟(chronobiotic 效应)和大脑内与睡眠相关的结构的平行和同时作用来解释。MLT 通过两种具有明显分布模式差异的高亲和力膜受体(MT1 和 MT2)发挥作用。MLT 是人类昼夜节律的强大同步器,因此 justifies 了在临床医学中使用 MLT 和 MLT 激动剂作为操纵睡眠-觉醒周期的药理学工具,并治疗睡眠障碍和其他昼夜节律障碍。现有的 MLT 类似物/药物都是非特异性的 MT1/MT2 激动剂。开发对每种亚型具有高度选择性的新型配体显然是该领域的新挑战,并且将成为治疗特定疾病(包括睡眠障碍)的新治疗剂的基础。